Multiple pathways via diverse endogenous receptors

The term Multiple pathways via diverse endogenous receptors does not identify a single, discrete therapeutic target such as a specific protein, enzyme, or ion channel. Instead, it serves as a descriptive phrase for polypharmacology, a phenomenon where a drug or substance exerts its biological effects by interacting with a wide variety of distinct molecular targets simultaneously (Peters, 2013, Nature Reviews Drug Discovery). This multi-target approach is frequently observed in complex therapeutic areas like neuropsychiatry and oncology, where the modulation of several signaling pathways is required to achieve clinical efficacy. However, because this entry represents a collection of disparate biological mechanisms rather than a unique, validatable gene product or protein complex, it is considered an incorrect or overly broad designation for a therapeutic target. From a drug development perspective, the lack of molecular specificity inherent in this description makes it impossible to perform standard target-based screening or to identify precise biomarkers for patient stratification.

Other names

PolypharmacologyMulti-target pharmacologyNon-specific receptor modulation

Not applicable as this refers to a broad pharmacological profile rather than a specific molecular interaction.